MEST, backed by full-cycle clinical evidence, wins FDA recognition as company eyes global expansion
A South Korean implantable medical device for knee osteoarthritis pain relief has received Breakthrough Device Designation from the US Food and Drug Administration.
OVMedi said Thursday that its knee osteoarthritis pain relief device, MEST, had received the designation and that the company would move forward with clinical trials and the regulatory approval process in the United States.
MEST is the world's first knee pain relief medical device to directly target the vastus medialis — the key muscle supporting knee load — rather than relying on conventional approaches such as intra-articular injections or joint replacement surgery. The implantable device supports weakened muscles and delivers microstimulation to alleviate knee pain.
OVMedi built its clinical evidence base through a comprehensive research program that began with neurophysiological basic mechanism studies in animal models, then progressed to randomized controlled trials — including exploratory and confirmatory clinical studies approved by South Korea's Ministry of Food and Drug Safety — as well as meta-analyses and real-world clinical research.
"Most FDA Breakthrough Device Designations earned by Korean companies have been concentrated in AI and diagnostic software," a company official said. "MEST's designation as an implantable medical device — one applied directly inside the patient's body — is drawing attention as an exceptional achievement."
The FDA's Breakthrough Device Designation is a program designed to accelerate the commercialization of innovative medical technologies that offer meaningful advantages over existing treatments for serious or life-threatening conditions causing irreversible physical dysfunction. Designated devices benefit from a dedicated FDA review team, early coordination throughout the approval process and priority review, significantly shortening the time to market. OVMedi added that the designation would also provide advantages when seeking reimbursement coverage under US health insurance programs after approval.
As a first-of-its-kind technology with no comparable precedent, MEST is expected to receive comprehensive FDA support throughout the process. The company is also pursuing regulatory approvals in Europe under CE MDR, as well as in the Philippines, Vietnam and Paraguay.
"Being designated as an FDA Breakthrough Device as an implantable medical device — not software or a diagnostic tool — is an unparalleled technological achievement," an OVMedi official said. "We will complete the FDA approval process on the strength of an evidence base built without gaps, from basic science through real-world clinical use."
freiheit@heraldcorp.com
